Sellas Life Sciences Group (ehemals Galena Biopharma) (Seite 88)
eröffnet am 30.10.12 22:43:19 von
neuester Beitrag 17.05.24 07:21:04 von
neuester Beitrag 17.05.24 07:21:04 von
Beiträge: 2.942
ID: 1.177.530
ID: 1.177.530
Aufrufe heute: 0
Gesamt: 345.982
Gesamt: 345.982
Aktive User: 0
ISIN: US81642T2096 · WKN: A2PU3T · Symbol: RXK3
1,3600
EUR
+1,80 %
+0,0240 EUR
Letzter Kurs 09:27:27 Tradegate
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,8000 | +45,45 | |
| 1,0000 | +42,86 | |
| 3,0000 | +42,18 | |
| 6,2500 | +24,75 | |
| 0,9600 | +18,93 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,2900 | -11,64 | |
| 114,60 | -13,61 | |
| 23,700 | -19,52 | |
| 1,3500 | -25,62 | |
| 0,7800 | -29,73 |
Beitrag zu dieser Diskussion schreiben
Feedback
Guten Morgen in die Runde!
Gale hat deren Ovarian Cancer Solution (301) gesternabend auf der ASCO convention vorgestellt, tja, wenn man die anschließende Kursverlauf etwas näher betrachtet, dann könnte man annehmen dass der Vortrag einige Teilnehmern wohl sehr gut gefallen hat
Galena Biopharma (GALE) to Present the GALE-301 Phase 1/2a Primary Analysis at ASCO
http://www.streetinsider.com/Corporate+News//Galena+Biopharm…
Ein paar interessanter statistiken im Bereich Gynecologic Cancer aus dem Beitrag anbei....
About Ovarian/Endometrial Cancers
New cases of ovarian cancer occur at an annual rate of 12.1 per 100,000 women in the U.S., with an estimated 21,290 cases for 2015. Although ovarian cancer represents about 1.3% of all cancers, it represents about 2.4% of all cancer deaths, or an estimated 14,180 deaths in 2015. Approximately 1.3% of women will be diagnosed with ovarian cancer at some point during their lifetime (2010 – 2012 data). The prevalence of ovarian cancer in the U.S. is about 192,000 women, and the five-year survivorship for women with ovarian cancer is 45.6%.
Due to the lack of specific symptoms, the majority of ovarian cancer patients are diagnosed at later stages of the disease, with an estimated 75% of women presenting with advanced-stage (III or IV) disease. These patients have their tumors routinely surgically debulked to minimal residual disease, and then are treated with platinum- and/or taxane-based chemotherapy. While many patients respond to this treatment regimen and become clinically free-of-disease, the majority of these patients will relapse. Depending upon their level of residual disease, the risk for recurrence after completion of primary therapy ranges from 60% to 85%. Unfortunately for these women, once the disease recurs, treatment options are limited and the disease remains incurable.
New cases of endometrial cancer occur at an annual rate of 25.1 per 100,000 women in the U.S., with an estimated 54,870 cases for 2015. Although endometrial cancer represents about 3.3% of all cancers, it represents about 1.7% of all cancer deaths, or an estimated 10,170 deaths in 2015. Approximately 2.8% of women will be diagnosed with endometrial cancer at some point during their lifetime (2010 – 2012 data). The prevalence of endometrial cancer in the U.S. is about 620,000 women, and the five-year survivorship for women with endometrial cancer is 81.7%.
Gale hat deren Ovarian Cancer Solution (301) gesternabend auf der ASCO convention vorgestellt, tja, wenn man die anschließende Kursverlauf etwas näher betrachtet, dann könnte man annehmen dass der Vortrag einige Teilnehmern wohl sehr gut gefallen hat
Galena Biopharma (GALE) to Present the GALE-301 Phase 1/2a Primary Analysis at ASCO
http://www.streetinsider.com/Corporate+News//Galena+Biopharm…
Ein paar interessanter statistiken im Bereich Gynecologic Cancer aus dem Beitrag anbei....
About Ovarian/Endometrial Cancers
New cases of ovarian cancer occur at an annual rate of 12.1 per 100,000 women in the U.S., with an estimated 21,290 cases for 2015. Although ovarian cancer represents about 1.3% of all cancers, it represents about 2.4% of all cancer deaths, or an estimated 14,180 deaths in 2015. Approximately 1.3% of women will be diagnosed with ovarian cancer at some point during their lifetime (2010 – 2012 data). The prevalence of ovarian cancer in the U.S. is about 192,000 women, and the five-year survivorship for women with ovarian cancer is 45.6%.
Due to the lack of specific symptoms, the majority of ovarian cancer patients are diagnosed at later stages of the disease, with an estimated 75% of women presenting with advanced-stage (III or IV) disease. These patients have their tumors routinely surgically debulked to minimal residual disease, and then are treated with platinum- and/or taxane-based chemotherapy. While many patients respond to this treatment regimen and become clinically free-of-disease, the majority of these patients will relapse. Depending upon their level of residual disease, the risk for recurrence after completion of primary therapy ranges from 60% to 85%. Unfortunately for these women, once the disease recurs, treatment options are limited and the disease remains incurable.
New cases of endometrial cancer occur at an annual rate of 25.1 per 100,000 women in the U.S., with an estimated 54,870 cases for 2015. Although endometrial cancer represents about 3.3% of all cancers, it represents about 1.7% of all cancer deaths, or an estimated 10,170 deaths in 2015. Approximately 2.8% of women will be diagnosed with endometrial cancer at some point during their lifetime (2010 – 2012 data). The prevalence of endometrial cancer in the U.S. is about 620,000 women, and the five-year survivorship for women with endometrial cancer is 81.7%.
Antwort auf Beitrag Nr.: 52.435.677 von Blackwater01 am 19.05.16 07:31:48
Hier den Link richtig eingestellt :
http://www.stockta.com/cgi-bin/analysis.pl?symb=GALE&cobrand…
Zitat von Blackwater01: Guten Morgen.....ich halte auch seid ein paar Tagen eine größere Posi von Gale im Depot.
Charttechnisch sieht es derzeit sehr gut aus :
http://www.stockta.com/cgi-bin/analysis.pl?symb=GALE&cobrand…
Sollten sich der grüne Verlauf heute weiter bestätigen....unter hohem Volumen...vermute ich stark..das es zum glattstellen der Kurzen kommen wird...
Ich hoffe das die Trials gut sein werden.....wenn es zu einem Buyout kommen sollte....hätte ich bei dem Marktpotenzial hier.....auch keinen Einwand
Good Luck den Investierten.....(Longs !)
Hier den Link richtig eingestellt :
http://www.stockta.com/cgi-bin/analysis.pl?symb=GALE&cobrand…
Guten Morgen.....ich halte auch seid ein paar Tagen eine größere Posi von Gale im Depot.
Charttechnisch sieht es derzeit sehr gut aus :
http://www.stockta.com/cgi-bin/analysis.pl?symb=GALE&cobrand…
Sollten sich der grüne Verlauf heute weiter bestätigen....unter hohem Volumen...vermute ich stark..das es zum glattstellen der Kurzen kommen wird...
Ich hoffe das die Trials gut sein werden.....wenn es zu einem Buyout kommen sollte....hätte ich bei dem Marktpotenzial hier.....auch keinen Einwand
Good Luck den Investierten.....(Longs !)
Charttechnisch sieht es derzeit sehr gut aus :
http://www.stockta.com/cgi-bin/analysis.pl?symb=GALE&cobrand…
Sollten sich der grüne Verlauf heute weiter bestätigen....unter hohem Volumen...vermute ich stark..das es zum glattstellen der Kurzen kommen wird...
Ich hoffe das die Trials gut sein werden.....wenn es zu einem Buyout kommen sollte....hätte ich bei dem Marktpotenzial hier.....auch keinen Einwand
Good Luck den Investierten.....(Longs !)
Antwort auf Beitrag Nr.: 52.435.050 von Growth2012 am 18.05.16 23:30:56Hi Growht. Das sind aber nicht die Ergebnisse die Ende Q2 präsentiert werden sollten, oder?
Möchte hier nicht NUR ShortSqueeze haben sondern auch nachhaltig investieren und bleiben.
Gruss
Andy
PS: ich habe richtige Schadensfreude gegeüber Shortgemeinde. Meine Gründe kennt ihr.
Möchte hier nicht NUR ShortSqueeze haben sondern auch nachhaltig investieren und bleiben.
Gruss
Andy
PS: ich habe richtige Schadensfreude gegeüber Shortgemeinde. Meine Gründe kennt ihr.
Oh dear, shorts are as of now "officially" in the shit....
Results are In - You should have bought/covered today!
-yr DFS was 41.4% in VG v 36% in CG (p= 0.70); however, in the OPT group, the 2-yr DFS was 64.3% v 36% in the CG (p= 0.03). Conclusions: This phase I/IIa trial utilizing E39 and booster inoculations to prevent recurrence in EC and OC pts has shown the vaccine to be safe and immunogenic. These results demonstrate the potential clinical benefit of E39 at the 1000mcg dose to prevent recurrence and that boosters may sustain this effect. These promising results will be further evaluated in a larger clinical trial. Clinical trial information: NCT01580696
After Hours : 1.53 Up 0.05 (3.38%)...to start with
Results are In - You should have bought/covered today!
-yr DFS was 41.4% in VG v 36% in CG (p= 0.70); however, in the OPT group, the 2-yr DFS was 64.3% v 36% in the CG (p= 0.03). Conclusions: This phase I/IIa trial utilizing E39 and booster inoculations to prevent recurrence in EC and OC pts has shown the vaccine to be safe and immunogenic. These results demonstrate the potential clinical benefit of E39 at the 1000mcg dose to prevent recurrence and that boosters may sustain this effect. These promising results will be further evaluated in a larger clinical trial. Clinical trial information: NCT01580696
After Hours : 1.53 Up 0.05 (3.38%)...to start with
Trading Spotlight
Antwort auf Beitrag Nr.: 52.426.587 von kusbas am 17.05.16 23:20:35@kusbas, gut gemeinte Rat, lass es doch lieber sein mit dem persönlichen 
Antwort auf Beitrag Nr.: 52.434.159 von Growth2012 am 18.05.16 20:59:06Hi growth, the ASCO conference findet heute statt
American Society of Clinical Oncology=One of the most important if not the most important meeting of the year in oncology.
sie sprechen alle miteinander
American Society of Clinical Oncology=One of the most important if not the most important meeting of the year in oncology.
sie sprechen alle miteinander
Die grüne kerze wird long, lang & länger...
...ich frage mich bloß, wann steigen die 1$ Fraktion demnach wieder ein
...ich frage mich bloß, wann steigen die 1$ Fraktion demnach wieder ein
Antwort auf Beitrag Nr.: 52.433.889 von kusbas am 18.05.16 20:31:34Analyst gives insight on GALE
FBR analyst Vernon Bernardino notes that the potential upside from NeuVax, a “significant near-term milestone” is undervalued. He explains the interim analysis of safety and futility expected in 2Q:16 is expected to be positive and “transformative” for the company, elaborating further that the interim should result in “lowered risk for NeuVax’s progression through late stage testing.”
>>>He also said “We expect the IDMC will recommend PRESENT “keep going,” and although a low probability, we think any observation that hints at NeuVax activity could be a major catalyst for the stock.”<<<
FBR analyst Vernon Bernardino notes that the potential upside from NeuVax, a “significant near-term milestone” is undervalued. He explains the interim analysis of safety and futility expected in 2Q:16 is expected to be positive and “transformative” for the company, elaborating further that the interim should result in “lowered risk for NeuVax’s progression through late stage testing.”
>>>He also said “We expect the IDMC will recommend PRESENT “keep going,” and although a low probability, we think any observation that hints at NeuVax activity could be a major catalyst for the stock.”<<<
Durchsuchen
